Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Evolus Expands International Presence With Launch Of Nuceiva In Spain

Author: Benzinga Newsdesk | June 12, 2024 08:04am

Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategy
Evolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionals

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.

Posted In: EOLS